+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Parkinson's Disease Therapeutics Market - Global Forecast 2026-2030- Product Image
Parkinson's Disease Therapeutics Market - Global Forecast 2026-2030- Product Image
New

Parkinson's Disease Therapeutics Market - Global Forecast 2026-2030

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5134266
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Parkinson’s Disease Therapeutics Market is experiencing significant transformation as new clinical breakthroughs, innovation in care delivery, and changing patient pathways require businesses to adapt with greater agility and precision.

Market Snapshot: Growth Trajectory and Business Drivers

The Parkinson’s Disease Therapeutics Market grew from USD 5.43 billion in 2024 to USD 5.76 billion in 2025 and is forecast to reach USD 7.83 billion by 2030, supported by a compound annual growth rate (CAGR) of 6.29%. This strong momentum can be attributed to accelerated neuroprotective research, wider adoption of device-led therapies, and broader integration of adjunctive, non-pharmacological options across the care continuum. Collaborations between clinical and commercial stakeholders are driving strategies that prioritize improved patient access, tailored management, and outcome-driven models. Evolving commercial priorities also reflect a heightened focus on operational resilience and supply chain optimization, as companies look to ensure seamless therapy delivery and maintain competitive positioning in a complex landscape.

Scope & Segmentation of the Parkinson’s Disease Therapeutics Market

This report delivers a detailed segmentation of the Parkinson’s Disease Therapeutics Market, supporting leaders with actionable intelligence on how shifts in therapy, delivery, and technology are shaping operational priorities and growth opportunities across regions. Each segment brings specific strategic considerations around access, value proposition, and care integration.

  • Drug Classes: Includes Anticholinergics, COMT Inhibitors, Dopamine Agonists, Levodopa, and MAO-B Inhibitors, along with agents such as Benztropine, Trihexyphenidyl, Entacapone, and Tolcapone. These categories form the pharmacological foundation for disease management strategies and present diverse opportunities for lifecycle innovation.
  • Therapy Types: Spans Medication and Non-Pharmacological modalities, incorporating Deep Brain Stimulation, Physiotherapy, plus Speech and Language Therapy. This broadened scope reflects evolving clinical guidelines favoring multidisciplinary interventions alongside traditional regimens.
  • Routes of Administration: Considers Infusion, Injectable, Oral, and Transdermal delivery models, each meeting distinct patient preferences and practice patterns.
  • Targeted Clinical Presentations: Covers Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson’s, Idiopathic Parkinson’s, and Vascular Parkinsonism. Solutions are increasingly tailored to individual diagnostic profiles, supporting precision care pathways.
  • Distribution Channels: Encompasses both Offline (Hospital and Retail Pharmacy) and Online models, allowing adaptive strategies to address provider reach and supply reliability.
  • End-User Settings: Features Clinics, Home Care, and Hospitals, each imposing unique challenges for packaging, dosing regimens, and patient support structures.
  • Regions: Analyzes the Americas, Europe, Middle East & Africa, and Asia-Pacific, highlighting localized trends in disease prevalence, policy drivers, and payer engagement.
  • Technologies: Reviews infusion systems, transdermal platforms, digital health tools, and tele-rehabilitation. Innovators are leveraging these advances to redefine monitoring, adherence, and personalization of therapy over time.

Key Takeaways for Senior Leadership

  • Integrated care models that combine pharmacological management, device technology, and rehabilitative services enhance value capture and offer greater differentiation in the market.
  • Changing regulatory frameworks and payer demands require sustained collection of real-world evidence and pragmatic clinical endpoints throughout development and commercialization stages.
  • Disease heterogeneity is shifting drug development toward tailored therapeutic approaches that go beyond standardized dopamine-focused regimens, enabling patient stratification and optimized care delivery.
  • Digital biomarkers and remote monitoring tools are empowering more agile, data-driven patient care and facilitating dynamic therapy adjustments across the continuum.
  • Regional adaptation of business models, including customized evidence packages and value dossiers aligned with local health-economic requirements, is vital for expanding access and payer acceptance.
  • Collaboration with digital health and rehabilitation technology partners is proving instrumental in broadening portfolios and enhancing market access potential.

Tariff Impact: Navigating US Commercial Policy Shifts

Recent US tariff introductions in 2025 have accelerated a reassessment of sourcing and supply chain strategies within the Parkinson’s Disease Therapeutics Market. Organizations have increased dual-sourcing and nearshoring of essential components, leading to strengthened manufacturing and distribution networks—especially for infusion and transdermal therapies. By enhancing supplier qualification processes and implementing redundant systems, companies have sought to minimize disruption, maintain optimal inventory, and ensure competitiveness in the face of ongoing policy uncertainty. These adjustments highlight the importance of operational resilience in a changing global regulatory landscape.

Methodology & Data Sources

This analysis leverages structured interviews with leading neurologists, pharmacy directors, payers, and procurement executives, augmented by an extensive review of clinical literature, regulatory documentation, and clinical trial results. The integration of primary and secondary sources ensures that findings are robust, current, and actionable for leadership decision-making.

Why This Report Matters

  • Delivers clarity on evolving intersections among science, care delivery, and innovative treatment models within Parkinson’s therapeutics, offering practical intelligence for guiding strategic planning.
  • Provides operational recommendations to fortify supply chain resilience and procurement agility in response to trade and policy fluctuation.
  • Enables evidence-driven research and commercialization, supporting readiness for shifting payer and regulatory requirements in global markets.

Conclusion

The Parkinson’s Disease Therapeutics Market necessitates nimble, evidence-based strategies. Organizations that harmonize scientific developments, integrated delivery modalities, and adaptive operations will be positioned to navigate risk and capture sustained growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2024
3.5. FPNV Positioning Matrix, 2024
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Parkinson's Disease Therapeutics Market, by Drug Class
8.1. Anticholinergics
8.1.1. Benztropine
8.1.2. Trihexyphenidyl
8.2. COMT Inhibitors
8.2.1. Entacapone
8.2.2. Tolcapone
8.3. Dopamine Agonists
8.4. Levodopa
8.5. MAO-B Inhibitors
9. Parkinson's Disease Therapeutics Market, by Therapy Type
9.1. Medications
9.2. Non-Pharmacological Therapies
9.2.1. Deep Brain Stimulation
9.2.2. Physiotherapy
9.2.3. Speech & Language Therapy
10. Parkinson's Disease Therapeutics Market, by Route Of Administration
10.1. Infusion
10.2. Injectable
10.3. Oral
10.4. Transdermal
11. Parkinson's Disease Therapeutics Market, by Targeted Area
11.1. Atypical Parkinsonian
11.2. Drug-Induced Parkinsonism
11.3. Genetic Parkinson's
11.4. Idiopathic Parkinson’s
11.5. Vascular Parkinsonism
12. Parkinson's Disease Therapeutics Market, by Distribution Channel
12.1. Offline
12.1.1. Hospital Pharmacy
12.1.2. Retail Pharmacy
12.2. Online
13. Parkinson's Disease Therapeutics Market, by End User
13.1. Clinics
13.2. Home Care
13.3. Hospitals
14. Parkinson's Disease Therapeutics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Parkinson's Disease Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Parkinson's Disease Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Parkinson's Disease Therapeutics Market
18. China Parkinson's Disease Therapeutics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2024
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2024
19.3. Product Portfolio Analysis, 2024
19.4. Benchmarking Analysis, 2024
19.5. AbbVie Inc.
19.6. Bayer AG
19.7. Biogen Inc.
19.8. Bristol-Myers Squibb Company
19.9. Eisai Co., Ltd.
19.10. Eli Lilly and Company
19.11. F. Hoffmann-La Roche Ltd.
19.12. GlaxoSmithKline plc
19.13. Merck & Co., Inc.
19.14. Otsuka Pharmaceutical Co., Ltd.
19.15. Pfizer Inc.
19.16. Teva Pharmaceutical Industries Limited
List of Figures
FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 14. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY GROUP, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ENTACAPONE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOLCAPONE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY GROUP, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY GROUP, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY GROUP, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY GROUP, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON’S, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON’S, BY GROUP, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON’S, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY GROUP, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 115. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 117. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 119. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 122. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 124. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 128. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 130. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 131. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 133. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 135. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 155. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 157. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 159. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 161. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 163. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 166. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 168. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 170. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 172. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 174. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 175. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 177. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 179. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 192. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 193. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 195. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 197. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 200. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 202. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 204. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 206. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 208. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 209. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 211. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 213. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 215. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 217. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 219. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 222. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 224. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 226. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 228. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 230. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 231. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 233. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 235. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 237. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 238. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 239. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 241. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 242. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 244. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 246. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 250. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 253. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 255. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 257. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 262. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 264. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 265. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 267. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 269. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 271. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 273. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 275. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 276. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
TABLE 278. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 280. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)

Companies Mentioned

The key companies profiled in this Parkinson's Disease Therapeutics market report include:
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amneal Pharmaceuticals LLC
  • Amyl Therapeutics SRL
  • Apotex Inc.
  • Aspen Neuroscience, Inc.
  • Bayer AG
  • Biogen Inc.
  • BlueRock Therapeutics LP by Bayer AG
  • Brainstorm Cell Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • Cerevance, LLC
  • Cipla Limited
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Muna Therapeutics ApS
  • Novartis AG
  • Orion Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Ltd.
  • UCB S.A.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.83 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030 - Product Image

Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Targeted Drugs for Parkinson's Disease Market - Global Forecast 2025-2030 - Product Image

Targeted Drugs for Parkinson's Disease Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Parkinsons Disease Market - Product Image

Parkinsons Disease Market

  • Report
  • 250 Pages
  • Global
From
Parkinson's Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Parkinson's Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Parkinson's Disease - Pipeline Insight, 2025 - Product Image

Parkinson's Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • 280 Pages
  • Global
From

About the Parkinson Drug Market

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life. The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.